search
Back to results

Prebiotics, Gut Microbiota, and Cardiometabolic Health

Primary Purpose

Prediabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Inulin
Placebo
Sponsored by
Virginia Polytechnic Institute and State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Prediabetes focused on measuring Prediabetes, prebiotics, metabolic endotoxemia

Eligibility Criteria

40 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Men and women; postmenopausal women not taking hormone replacement therapy.
  • Fasting glucose between 5.6 - 6.9 mmol/L and/or a 2h plasma glucose between 7.8-11.1 mmol/L following a 75 g oral glucose tolerance test.
  • Weight stable for previous 6 months (+/- 2.0 kg).
  • Sedentary to recreationally active
  • Willing to be randomized to treatment or placebo.
  • Verbal and written informed consent.
  • No plans to gain/lose weight or change physical activity level.
  • Willing to pick up food daily, and consume foods provided for the 6-week controlled feeding period.

Exclusion Criteria:

  • BMI less than 25 kg/m2 or greater than 40 kg/m2 or body mass greater than 300 pounds due to limit of DEXA.
  • Diabetes or diabetes medications
  • Prebiotic or probiotic supplement or product consumption in prior 3 months.
  • Total cholesterol > 6.2 mmol/L; triglycerides > 4.5 mmol/L.
  • Blood pressure > 140/90 mmHg or antihypertensive medications.
  • Diagnosed inflammatory disease (e.g. lupus, irritable bowel, periodontal disease, etc)
  • Fructo, galacto-, xylo-oligosaccharide intake > 3 g/day.
  • Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease.
  • Smoking, alcohol consumption > 2 servings /d for males and 1 serving/d for females, or taking medications (including but not limited to statins or other drugs with anti-inflammatory actions) or antioxidant vitamins or supplements.
  • Known allergy, hypersensitivity, or intolerance to inulin.

Sites / Locations

  • Virginia Polytechnic and State University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Inulin

Placebo

Arm Description

Participants will receive 10 g of inulin powder each day for 6 weeks.

Participants will receive 10 g of maltodextrin each day for 6 weeks.

Outcomes

Primary Outcome Measures

Change in insulin sensitivity.
Insulin sensitivity will be assessed via a frequently sampled intravenous glucose tolerance test.

Secondary Outcome Measures

Change in metabolic flexibility.
Metabolic flexibility will be measured in skeletal muscle biopsies prior to and 4 hours following a high fat meal.
Change in endothelial function.
Flow mediated dilation of the brachial artery will be assessed using duplex ultrasonography with a high resolution linear array transducer according to published guidelines.
Change in arterial stiffness.
Arterial stiffness will be measured via carotid femoral pulse wave velocity.

Full Information

First Posted
January 7, 2015
Last Updated
August 31, 2023
Sponsor
Virginia Polytechnic Institute and State University
search

1. Study Identification

Unique Protocol Identification Number
NCT02346838
Brief Title
Prebiotics, Gut Microbiota, and Cardiometabolic Health
Official Title
The Effect of Prebiotics on Insulin Sensitivity, Metabolic Flexibility, and Cardiovascular Health in Prediabetic Adults.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
July 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Virginia Polytechnic Institute and State University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Forty-eight prediabetic men and women (50-75 years of age) will participate in a 6-week feeding study in which they will randomized to receive either 10 g/day of inulin or placebo. All subjects will be fed an isocaloric diet (50% carbohydrate, 35% fat, 15% protein,) controlled for micronutrient content for 6 weeks to avoid the potential confound of individual differences in diet on gut microbiota. Measurements of intestinal permeability, insulin sensitivity, and skeletal muscle metabolic flexibility will be made prior to and following the controlled feeding period. Stool samples will be collected to assess gut microbial communities.
Detailed Description
Prebiotics have been defined as "selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring health benefit(s) upon host health". Commonly used prebiotics are inulin-type fructans, fructo-oligosaccharides, xylo-oligosaccharides and galacto-oligosaccharides and while all prebiotics are fibers, not all fibers are prebiotics. The proliferation of a targeted bacterial species, in particular, Bifiodobacterium spp. and Lactobacillus spp. contribute to host cardiometabolic health in many ways including, but not limited to, short chain fatty acid production and, modulation of gut barrier function, endotoxin concentrations, inflammatory pathways, and energy metabolism however, to our knowledge the potential benefits of prebiotic supplementation on cardiometabolic dysfunction has received little attention. Although the concept that dysbiosis of the gut microbiota leads to metabolic endotoxemia and increased risk of cardiometabolic disease is novel, very little information is available in humans. The significance of our proposal includes providing proof of concept efficacy of prebiotic supplementation with inulin on cardiometabolic dysfunction and assessing its relation with changes in gut bacterial communities, intestinal permeability, and metabolic endotoxemia in prediabetes, a condition affecting a substantial segment of the population. Our study could lead to the identification of prebiotic supplementation with inulin as a simple and efficacious strategy for reducing cardiometabolic risk in prediabetes which could change clinical practice by informing dietary recommendations and increasing acceptance of prebiotics by the scientific and medical community.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prediabetes
Keywords
Prediabetes, prebiotics, metabolic endotoxemia

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inulin
Arm Type
Experimental
Arm Description
Participants will receive 10 g of inulin powder each day for 6 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive 10 g of maltodextrin each day for 6 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin
Other Intervention Name(s)
Prebiotic
Intervention Description
The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
Primary Outcome Measure Information:
Title
Change in insulin sensitivity.
Description
Insulin sensitivity will be assessed via a frequently sampled intravenous glucose tolerance test.
Time Frame
Baseline, 6 weeks
Secondary Outcome Measure Information:
Title
Change in metabolic flexibility.
Description
Metabolic flexibility will be measured in skeletal muscle biopsies prior to and 4 hours following a high fat meal.
Time Frame
Baseline, 6 weeks
Title
Change in endothelial function.
Description
Flow mediated dilation of the brachial artery will be assessed using duplex ultrasonography with a high resolution linear array transducer according to published guidelines.
Time Frame
Baseline, 6 weeks
Title
Change in arterial stiffness.
Description
Arterial stiffness will be measured via carotid femoral pulse wave velocity.
Time Frame
Baseline, 6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Men and women; postmenopausal women not taking hormone replacement therapy. Fasting glucose between 5.6 - 6.9 mmol/L and/or a 2h plasma glucose between 7.8-11.1 mmol/L following a 75 g oral glucose tolerance test. Weight stable for previous 6 months (+/- 2.0 kg). Sedentary to recreationally active Willing to be randomized to treatment or placebo. Verbal and written informed consent. No plans to gain/lose weight or change physical activity level. Willing to pick up food daily, and consume foods provided for the 6-week controlled feeding period. Exclusion Criteria: BMI less than 25 kg/m2 or greater than 40 kg/m2 or body mass greater than 300 pounds due to limit of DEXA. Diabetes or diabetes medications Prebiotic or probiotic supplement or product consumption in prior 3 months. Total cholesterol > 6.2 mmol/L; triglycerides > 4.5 mmol/L. Blood pressure > 140/90 mmHg or antihypertensive medications. Diagnosed inflammatory disease (e.g. lupus, irritable bowel, periodontal disease, etc) Fructo, galacto-, xylo-oligosaccharide intake > 3 g/day. Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease. Smoking, alcohol consumption > 2 servings /d for males and 1 serving/d for females, or taking medications (including but not limited to statins or other drugs with anti-inflammatory actions) or antioxidant vitamins or supplements. Known allergy, hypersensitivity, or intolerance to inulin.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kevin P Davy, PhD
Organizational Affiliation
Virginia Polytechnic and State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Virginia Polytechnic and State University
City
Blacksburg
State/Province
Virginia
ZIP/Postal Code
24061
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Prebiotics, Gut Microbiota, and Cardiometabolic Health

We'll reach out to this number within 24 hrs